Carisma Therapeutics, Inc.CARMNASDAQ
Loading
R&D Expenses Over TimeContracting
Percentile Rank79
3Y CAGR-21.5%
5Y CAGR+3.3%
Year-over-Year Change
Research and development spending
3Y CAGR
-21.5%/yr
vs +42.1%/yr prior
5Y CAGR
+3.3%/yr
Recent deceleration
Acceleration
-63.7pp
Decelerating
Percentile
P79
Within normal range
vs 5Y Ago
1.2x
Modest growth
Streak
2 yr
Consecutive declineContracting
| Period | Value | YoY Change |
|---|---|---|
| TTM | $27.36M | -54.2% |
| 2024 | $59.67M | -19.5% |
| 2023 | $74.13M | +30.9% |
| 2022 | $56.62M | +124.4% |
| 2021 | $25.23M | +8.3% |
| 2020 | $23.29M | -4.7% |
| 2019 | $24.44M | +76.2% |
| 2018 | $13.87M | +13.4% |
| 2017 | $12.22M | +0.2% |
| 2016 | $12.20M | - |